Will gene therapies finally be commercially viable to pharma?
Our latest Free Thinking white paper explores the science behind the idea of gene therapy and takes a look at some of the core challenges medical researchers have faced when attempting to develop this technology. We review gene therapy’s chequered past, look at recent developments in this field and consider the future for gene therapies on their way to market.
Genes are segments of DNA which code instructions for your cells to make proteins. Many inherited disorders are a result of faulty genes which encode incorrect instructions for making specific proteins, either the proteins themselves are defective or the gene may have faulty expression which can result in over-expression so over-production of a certain kind of protein. In the case of cancer, there can be multiple external and internal factors which lead to production of genetically mutated cancerous cells.
US Presidential Election: The legacy of the Affordable Care Act and the future for healthcare
Our latest Free Thinking white paper explores the legacy of the Affordable Care Act and the future for healthcare
As US citizens prepare to vote for a new President on Tuesday 8th November, we ask, what is the likely impact of a Republican or Democrat win on the future of the ACA, the health system and the pharma industry?
We spoke to John Leifer, author and strategic consultant to the healthcare industry, to see which way he thinks the wind is blowing.
EULAR Annual European Congress of Rheumatology 2016
8-11 June 2016, London
Research Partnership is delighted to be attending the EULAR Annual European Congress of Rheumatology in June. Since its introduction in 2000, the congress has become the primary platform for exchange of scientific and clinical information in Europe. With more than 16,000 delegates from all over the world registered at the EULAR Congress 2011 in London, this year’s London Congress is hoping to surpass all previous records.
Leveraging the ASEAN market
If you can only research one ASEAN market, which one do you choose? Our Free Thinking paper investigates the opportunities for pharma in ASEAN and outlines the factors you need to consider in deciding which markets to research.
Home to over half a billion people, the 10 nations that make up the ASEAN region constitute the eighth largest economy in the world. With pharmaceutical sales projected to exceed $20 billion in 2014, it’s an increasingly attractive and dynamic growth market for pharma manufacturers.